Compare Enovix Corporation (ENVX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs TG Therapeutics Inc — how do they compare? Enovix Corporation trades at $4.56 (market cap $1.06B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 7.2× Enovix Corporation's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | TGTX | |
|---|---|---|
Market Cap | $1.06B | $7.64B |
Sector | Technology | Health |
52-Week High | $13.19 | $59.06 |
52-Week Low | $3.68 | $26.94 |
Enterprise Value | $1.07B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.73, up 1.94% with a bullish technical signal despite negative profitability metrics. The company shows consistent earnings beats but operates at significant losses with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple executive as COO and upcoming Q2 2026 earnings on August 12, 2026.
Analyst consensus remains strongly bullish with a $12.38 price target (162% upside), though execution risks are high given cash burn and negative margins. The stock offers speculative growth potential in advanced battery technology but requires careful risk management due to ongoing operational losses.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
